-DOCSTART- -X- O
Although -X- _ O
vesicular -X- _ B-Intervention
stomatitis -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
VSV -X- _ I-Intervention
) -X- _ I-Intervention
neurovirulence -X- _ O
and -X- _ O
pathogenicity -X- _ O
in -X- _ O
rodents -X- _ O
have -X- _ O
been -X- _ O
well -X- _ O
studied -X- _ O
, -X- _ O
little -X- _ O
is -X- _ O
known -X- _ O
about -X- _ O
VSV -X- _ B-Intervention
pathogenicity -X- _ I-Intervention
in -X- _ O
non-human -X- _ B-Patient
primates. -X- _ I-Patient
To -X- _ O
address -X- _ O
this -X- _ O
question -X- _ O
, -X- _ O
we -X- _ O
measured -X- _ O
VSV -X- _ B-Outcome
viremia -X- _ I-Outcome
, -X- _ I-Outcome
shedding -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
neurovirulence -X- _ I-Outcome
in -X- _ O
macaques. -X- _ B-Patient
Following -X- _ O
intranasal -X- _ B-Intervention
inoculation -X- _ I-Intervention
, -X- _ O
macaques -X- _ B-Patient
shed -X- _ O
minimal -X- _ B-Intervention
recombinant -X- _ I-Intervention
VSV -X- _ I-Intervention
( -X- _ I-Intervention
rVSV -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ O
nasal -X- _ O
washes -X- _ O
for -X- _ O
one -X- _ O
day -X- _ O
post-inoculation -X- _ O
; -X- _ O
viremia -X- _ B-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
detected. -X- _ I-Outcome
Following -X- _ O
intranasal -X- _ B-Intervention
inoculation -X- _ I-Intervention
of -X- _ O
macaques -X- _ B-Patient
, -X- _ O
wild -X- _ B-Intervention
type -X- _ I-Intervention
( -X- _ I-Intervention
wt -X- _ I-Intervention
) -X- _ I-Intervention
VSV -X- _ I-Intervention
, -X- _ I-Intervention
rVSV -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
two -X- _ I-Intervention
rVSV-HIV -X- _ I-Intervention
vectors -X- _ O
showed -X- _ O
no -X- _ B-Outcome
evidence -X- _ I-Outcome
of -X- _ I-Outcome
spread -X- _ I-Outcome
to -X- _ I-Outcome
CNS -X- _ I-Outcome
tissues. -X- _ I-Outcome
However -X- _ O
, -X- _ O
macaques -X- _ B-Patient
inoculated -X- _ B-Outcome
intrathalamically -X- _ I-Outcome
with -X- _ I-Outcome
wt -X- _ I-Outcome
VSV -X- _ I-Outcome
developed -X- _ I-Outcome
severe -X- _ I-Outcome
neurological -X- _ I-Outcome
disease. -X- _ I-Outcome
One -X- _ B-Patient
of -X- _ I-Patient
four -X- _ I-Patient
macaques -X- _ I-Patient
receiving -X- _ O
rVSV -X- _ B-Intervention
developed -X- _ B-Outcome
clinical -X- _ I-Outcome
and -X- _ I-Outcome
histological -X- _ I-Outcome
signs -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
wt -X- _ I-Outcome
group -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
the -X- _ I-Outcome
remaining -X- _ I-Outcome
three -X- _ I-Outcome
macaques -X- _ I-Outcome
in -X- _ I-Outcome
this -X- _ I-Outcome
group -X- _ I-Outcome
and -X- _ I-Outcome
all -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
macaques -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
rVSV-HIV -X- _ I-Outcome
vector -X- _ I-Outcome
groups -X- _ I-Outcome
showed -X- _ I-Outcome
no -X- _ I-Outcome
clinical -X- _ I-Outcome
signs -X- _ I-Outcome
of -X- _ I-Outcome
disease -X- _ I-Outcome
and -X- _ I-Outcome
reduced -X- _ I-Outcome
severity -X- _ I-Outcome
of -X- _ I-Outcome
histopathology -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
wt -X- _ I-Outcome
group. -X- _ I-Outcome
The -X- _ O
implications -X- _ O
of -X- _ O
these -X- _ O
findings -X- _ O
for -X- _ O
rVSV -X- _ O
vaccine -X- _ O
development -X- _ O
are -X- _ O
discussed -X- _ O
. -X- _ O

